ST Wanbang's Myasthenia Gravis Drug WP107 Gains FDA Approval for Clinical Trials

ST Wanbang's subsidiary, Wanbangde Pharmaceutical Group, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a multi-dose dose-climbing clinical trial for its new drug, WP107. This drug is an oral solution of Huperzine A and is intended for the treatment of generalized myasthenia gravis. The approval allows for studies in healthy trial participants. AI

RANK_REASON The item describes regulatory approval for a new drug's clinical trial, which falls under research and policy. [lever_c_demoted from research: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

• Huperzine A
• myasthenia gravis
• ST Wanbang
• U.S. Food and Drug Administration
• Wanbangde Pharmaceutical Group
• WP107

• product
• policy

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →